TOVX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TOVX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Theriva Biologics's total current assets for the quarter that ended in Dec. 2024 was $16.28 Mil.
The historical data trend for Theriva Biologics's Total Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theriva Biologics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Total Current Assets | Get a 7-Day Free Trial |
![]() |
![]() |
7.93 | 68.86 | 45.52 | 27.40 | 16.28 |
Theriva Biologics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Total Current Assets | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
27.40 | 21.66 | 19.72 | 19.53 | 16.28 |
Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.
Theriva Biologics's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 11.609 | + | 3.323 | + | 0 | + | 1.349 | |
= | 16.28 |
Theriva Biologics's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 11.609 | + | 3.323 | + | 0 | + | 1.349 | |
= | 16.28 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Theriva Biologics (AMEX:TOVX) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Theriva Biologics's Liquidation Value for the quarter that ended in Dec. 2024 is
Liquidation value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 11.609 | - | 16.285 | + | 0.75 * 0 | + | 0.5 * 0 |
= | -4.68 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Theriva Biologics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Steven A Shallcross | director, officer: CEO and CFO | C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4 |
Francis Tufaro | officer: Chief Operating Officer | 9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850 |
John J Monahan | director | |
Scott Tarriff | director | 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430 |
Randal J Kirk | 10 percent owner | 1881 GROVE AVENUE, RADFORD VA 24141 |
Joseph A. Sliman | officer: CHIEF MEDICAL OFFICER | 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850 |
Jeffrey Scott Riley | director | C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108 |
Intrexon Corp | 10 percent owner | 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876 |
Charles Evan Ballantyne | officer: CHIEF FINANCIAL OFFICER | 27 HEARTHSTONE ROAD, HOPKINTON MA 01748 |
Nelson K. Stacks | director | C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108 |
Lyon Lyman Max Jr | director, officer: CEO & President | C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108 |
David A. Newsome | officer: Chief Scientific Officer | 3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108 |
James S Kuo | director | 509 MADISON AVE 14TH FL, NEW YORK NY 10022 |
Daniel J Dorman | director | |
Wayne George Holman | 10 percent owner | 430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By GuruFocus Research • 02-15-2024
By GuruFocus Research • 02-15-2024
By GuruFocus Research • 02-15-2024
By GuruFocus Research • 02-15-2024
By PRNewswire PRNewswire • 07-25-2022
By GuruFocus Research GuruFocus Editor • 02-03-2023
By GuruFocus Research • 02-15-2024
By GuruFocus Research • 02-15-2024
By GuruFocus Research • 02-15-2024
By GuruFocus Research GuruFocus Editor • 01-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.